IQInvest research note
25 SEP 2026 · 23:59 ET
BMY
Bristol-Myers Squibb Company
$62.86
$1.36 (+2.21%)up 2.21%
25 September 2026 · delayed 15+ min
C-
Cut-offs are the grader's own: 97+ for an A+, below 60 is an F.
Bristol-Myers Squibb Company earns a C- on good profit margins (>10%) and strong ROE (>20%) but high debt-to-equity ratio (>2.0) and MACD bearish (negative histogram). Reasonable investment with moderate upside potential.
Adjusted for Moderate investors, Medium-term investors 6.0% suggested allocation Change these
IQ-BMY-20260925engine v1 · 7-category weighted scorecard